HC2

(redirected from Hybrid Capture 2)
AcronymDefinition
HC2Hybrid Capture 2
References in periodicals archive ?
Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol.
(a) ThinPrep (Hologic, Bedford, Massachusetts); SurePath (Becton, Dickinson and Company, Franklin Lakes, New Jersey); Digene (Qiagen, Gaithersburg, Maryland); Digene Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, Maryland); Cervista (Hologic, Bedford, Massachusetts); cobas 4800 (Roche, Pleasanton, California); Gen-Probe Aptima (Hologic, Bedford, Massachusetts).
The last FDA-cleared molecular assay discussed in this article, will be the Hybrid Capture 2 High-Risk HPV DNA test by Qiagen, Inc.
Presently, the two assays most widely used for the detection of genital types are PCR with generic primers and the Hybrid Capture 2 assay (Digene Corp, Gaithersburg, MD, USA).
Aetna covers HPV DNA testing for patients with atypical squamous cells of undetermined significance using the Hybrid Capture 2 technique, and the insurer's clinical poli cy council will consider the information submitted to the FDA on the use of the test as a screening device, along with oth er relevant new clinical data as they are published, said company spokeswoman Elizabeth Sell, Philadelphia.
[Study included ThinPrep, SurePath, Hybrid Capture 2 assay.]
According to international guidelines (4) for validation of hrHPV DNA tests, candidate assays should demonstrate clinical noninferiority to an established and clinically validated reference assay, such as Hybrid Capture 2 (HC2; Qiagen, Valencia, California) or [GP5.sup.+]/[6.sup.+] polymerase chain reaction (PCR).
Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV test and Hybrid Capture 2 in population-based cervical cancer screen-ing.
Participants were randomized to primary screening with the HPV DNA test (hybrid capture 2) or to conventional cytology.
Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of High-Risk Human Papillomavirus and Diagnosis of Biopsy-Confirmed High Grade Cervical Disease.
Aetna currently covers HPV DNA testing for patients with atypical squamous cells of undetermined significance using the Hybrid Capture 2 technique.